September 15, 2017

September 15, 2017

Harmonic Drive describe surgical robots and their potential
News Medical – Sept. 15
There are three main types of surgical robot: autonomous, dependent and shared-control. Writing in Cancer Control, journal of the Moffitt Cancer Center, the authors Doulgeris, Gonzales-Blohm and Filis et al, explain that "autonomous systems reproduce programmed motions ... dependent systems [are where] the surgeon maintains full control of the system at all times ... [and] shared-control systems are a hybrid.

Moffitt Earns 2017 Leading Disability Employer Seal from National Organization on Disability
Press Release Point – Sept. 14
The National Organization on Disability (NOD) announced Moffitt Cancer Center is among 45 organizations that have been selected to receive the 2017 NOD Leading Disability Employer Seal™. 

ESMO 2017: PACIFIC Trial: Durvalumab Improves Progression-Free Survival in Stage III Lung Cancer
ASCO Post – Sept. 14
The PACIFIC trial is being conducted at 235 centers in 26 countries, and Scott Antonia, MD, PhD, from the Moffitt Cancer Center is the lead investigator.

Savills Studley Represents Moffitt Cancer Center in $11.75M Acquisition
Savills-Studley – Sept. 13
Savills Studley, the leading commercial real estate firm specializing in tenant representation, arranged an $11.75 million acquisition on behalf of Moffitt Cancer Center & Research Institute 

Advancing the Hematology Field
Celgene – Sept. 13
Alan F. List, MD, president and CEO of the Moffitt Cancer Center in Tampa, has made many contributions to hematology. List remains focused on what he has to offer the hematology field, so, last December, when he was recognized with the 2016 Celgene Career Achievement Award, he was humbly grateful.

Cloud, Mobile Strategies Critical to HIT Infrastructure Growth
HIT Infrastructure – Sept. 13
Developing an HIT infrastructure strategy helps organizations move from legacy to modern IT systems according to Moffitt Cancer Center CTO Tom Hull

Pale is the new tan, dermatologists tell patients
St. Augustine Record – Sept. 13
Tourists and residents in Florida can avoid the possible fatal outcomes from skin cancer with a game plan, said Dr. Nikhil Khushalani, one of the top cancer doctors at Tampa’s Moffitt Cancer Center, which is the National Cancer Institute’s only designated Comprehensive Cancer Center in Florida.

Peregrine Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial Evaluating Bavituximab Treatment Combination in Patients with Newly Diagnosed Glioblastoma – Sept. 13
"We look forward to following this important study at the Massachusetts General Hospital Cancer Center, as well as the planned trials at the Moffitt Cancer Center and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins," said Joseph Shan, MPH, vice president, clinical and regulatory affairs of Peregrine.

Ways to prevent and never get cancer
TVC News – Sept. 12
First, the good news: You probably won’t get cancer. That is, if you have a healthy lifestyle. “As many as 70% of known causes of cancers are avoidable and related to lifestyle,” says Thomas A. Sellers, PhD, associate director for cancer prevention and control at Moffitt Cancer Center in Tampa.

CDC Report: Only 43 percent of US teens are receiving full HPV vaccination
My Informs – Sept. 12
“The results of this study support comprehensive vaccination programs,” said Anna Giuliano, a study co-author and director of the Center for Infection Research in Cancer at the Moffitt Cancer Center in Tampa, Florida, according to Seeker.

Durvalumab improves progression-free survival in stage III lung cancer
Medical Xpress – Sept. 11
The trial is being conducted at 235 centres in 26 countries, and Dr Scott Antonia from the Moffitt Cancer Center is the lead investigator. It included 713 patients who were randomised 2:1 to receive durvalumab 10 mg/kg every two weeks or placebo for up to 12 months. 

Grants: Funding Florida’s Research
Florida Trend – Sept. 11
Lee Moffitt Cancer Center, Tampa – 35; 15.72

How to design a network that meets all of your users' needs
Tech Republic – Sept. 11
At the VMworld 2017 conference, Moffitt Cancer Center CTO Tom Hull talked about how the hospital designed a network that met its users different needs.

HPV Vaccine Shows Great Promise in Fighting Cancer
Seeker – Sept. 11
“The results of this study support comprehensive vaccination programs,” said Anna Giuliano, a study co-author and director of the Center for Infection Research in Cancer at the Moffitt Cancer Center in Tampa, in a press release.

Moffitt Cancer Center Showcases Its Blueprint for Building a Best-in-Class Precision Medicine Program at PierianDx-Hosted Webinar D
igital Journal – Sept. 11
PierianDx, the forerunner in clinical genomic analysis, interpretation and reporting, will host a webinar featuring Moffitt Cancer Center’s journey to design a world-class precision medicine program.

Survival Rates Compared for Durvalumab vs. Placebo in NSCL
MPR – Sept. 11
Scott J. Antonia, MD, PhD, from the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida, and colleagues randomized 709 patients with stage III NSCLC in a 2:1 ratio to receive durvalumab (473 patients) or placebo (236 patients) every two weeks for up to one year.

10 Top Cancer Experts Reveal What They Do To Avoid The Deadly Disease
General Health Magazine – Sept. 11
Philippe Spiess, M.D., a genitourinary oncologist at Moffitt Cancer Center, eats what he calls a “power egg breakfast wrap.” He heats 1/4 cup of frozen spinach in a pan and mixes it with an egg and 200 milliliters (nearly a cup) of egg white. 

The Signs Of Ovarian Cancer EVERY Woman Should Know About
Women’s Health Magazine – Sept. 11
Obviously, these are all things that can happen with a slew of illnesses or just life in general, but persistence and frequency is important, says Mian M. K. Shahzad, M.D., Ph.D., a gynecologic oncologist at Moffitt Cancer Center. Also seen at

New HPV Vaccine Reduces The Risk Of HPV-Related Diseases
Med India – Sept. 11
The research team along with those from Moffitt Cancer Center published their final results in The Lancet showing that the newest 9vHPV vaccine is highly effective in preventing HPV infection and disease. 

Tips for desiging your network to meet the needs of different sets of users
Tech Republic – Sept. 11
The Moffitt Cancer Center has compliance needs that it must meet, but also has users who want more network freedom.

Positioning 177-Lu-Dotatate Therapy and 68-Ga-Dotatate Scans in Management of Neuroendocrine Tumors
ASCO Post – Sept. 10
At the 2017 Gastrointestinal Cancers Symposium, principal investigator of NETTER-1, Jonathan Strosberg, MD, of Moffitt Cancer Center in Tampa, Florida, brought listeners up-to-date on this effective second-line therapy and looked ahead to future treatments of neuroendocrine tumors.

Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma
USA Life Sciences Database – Sept. 10
"Patients with hepatocellular carcinoma face a very poor prognosis with few therapeutic options," said Richard Kim, M.D., Associate Professor, Moffitt Cancer Center, an investigator for the study.

Durvalumab Delays Lung Cancer Progression After Chemoradiotherapy
Oncology Times – Sept. 9
The trial is ongoing at 235 centers in 26 countries under lead investigator Scott J. Antonia, MD PhD, Chair, Department of Thoracic Oncology at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Fla.

IoT presents new opportunities and challenges for healthcare facilities
Tech Republic – Sept. 8
"The Internet of Things has expanded the playing field of all the things that are attached to our network," Tom Hull, Moffitt Cancer Center's CTO said. 

New AML approvals changing the treatment landscape
PM 360 Online – Sept. 8
Those outcomes are a long way off, but appreciable incremental gains may lie ahead with the recent advances in AML therapy, said Dr. Lancet, chair of the department of malignant hematology at Moffitt Cancer Center in Tampa.


Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.